397 related articles for article (PubMed ID: 16283534)
41. Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial.
Takahashi F; Morita S
J Biopharm Stat; 2018; 28(5):870-883. PubMed ID: 29420118
[TBL] [Abstract][Full Text] [Related]
42. Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain.
Hooker BA; Tobon G; Baker SJ; Zhu C; Hesterman J; Schmidt K; Rajagovindan R; Chandran P; Joshi SK; Bannon AW; Hoppin J; Beaver J; Fox GB; Day M; Upadhyay J
Eur J Pain; 2014 Feb; 18(2):223-37. PubMed ID: 23857727
[TBL] [Abstract][Full Text] [Related]
43. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics/pharmacodynamics model-supported early drug development.
Chen B; Dong JQ; Pan WJ; Ruiz A
Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
[TBL] [Abstract][Full Text] [Related]
45. Gabapentin for Chronic Neuropathic Pain.
Garcia D
Am Fam Physician; 2015 Dec; 92(11):Online. PubMed ID: 26760423
[No Abstract] [Full Text] [Related]
46. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic/pharmacodynamic studies in drug product development.
Meibohm B; Derendorf H
J Pharm Sci; 2002 Jan; 91(1):18-31. PubMed ID: 11782894
[TBL] [Abstract][Full Text] [Related]
48. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
49. The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function.
Munro G; Storm A; Hansen MK; Dyhr H; Marcher L; Erichsen HK; Sheykhzade M
Pharmacol Biochem Behav; 2012 May; 101(3):465-78. PubMed ID: 22366217
[TBL] [Abstract][Full Text] [Related]
50. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.
Pillai GC; Mentré F; Steimer JL
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):161-83. PubMed ID: 16283536
[TBL] [Abstract][Full Text] [Related]
51. Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.
Parasrampuria DA; Benet LZ; Sharma A
AAPS J; 2018 Mar; 20(3):46. PubMed ID: 29536211
[TBL] [Abstract][Full Text] [Related]
52. PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK-PD modeling from nonclinical to clinical development.
Oggianu L; Garrone B; Fiorentini F; Del Bene F; Rosignoli MT; Di Giorgio FP; Kaminski RM
Clin Transl Sci; 2023 Apr; 16(4):606-617. PubMed ID: 36785922
[TBL] [Abstract][Full Text] [Related]
53. Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches.
Hanna D; Romero K; Schito M
Int J Infect Dis; 2017 Mar; 56():208-211. PubMed ID: 27789338
[TBL] [Abstract][Full Text] [Related]
54. Application of Clinical Pharmacology Principles in Drug Development of Modified-Release Products: Leveraging Exposure-Response Information to Support Approval.
AbuAsal BS; Hamed SS; Ahmed MA; Al-Mansour L; Uppoor R; Mehta M
J Clin Pharmacol; 2020 Nov; 60(11):1441-1452. PubMed ID: 32453882
[TBL] [Abstract][Full Text] [Related]
55. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.
Nestorov I; Graham G; Duffull S; Aarons L; Fuseau E; Coates P
Pharm Res; 2001 Aug; 18(8):1210-9. PubMed ID: 11587494
[TBL] [Abstract][Full Text] [Related]
56. A Bayesian paradigm for decision-making in proof-of-concept trials.
Pulkstenis E; Patra K; Zhang J
J Biopharm Stat; 2017; 27(3):442-456. PubMed ID: 28166459
[TBL] [Abstract][Full Text] [Related]
57. Role of modelling and simulation in Phase I drug development.
Aarons L; Karlsson MO; Mentré F; Rombout F; Steimer JL; van Peer A;
Eur J Pharm Sci; 2001 May; 13(2):115-22. PubMed ID: 11297895
[TBL] [Abstract][Full Text] [Related]
58. Use of statistical and pharmacokinetic-pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference.
Kimko H; Berry S; O'Kelly M; Mehrotra N; Hutmacher M; Sethuraman V
J Biopharm Stat; 2017; 27(3):554-567. PubMed ID: 28304215
[TBL] [Abstract][Full Text] [Related]
59. Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.
Vozmediano V; Sologuren A; Lukas JC; Leal N; Rodriguez M
Pharm Res; 2017 Dec; 34(12):2720-2734. PubMed ID: 28971281
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.
Garralda E; Dienstmann R; Tabernero J
Am Soc Clin Oncol Educ Book; 2017; 37():210-215. PubMed ID: 28561730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
